WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk
Diabetic cardiomyopathy increases mortality in diabetic patients by causing heart failure and is characterized by a multitude of interrelated systems that are influenced, including calcium homeostasis, renin-angiotensin system, protein kinase C signaling pathway, metabolism, mitochondria, fibrosis, and oxidative stress [89]
Bergs V
That's one reason why results vary from person to person
3 million Canadians use GLP-1 drugs
Dietary Modifications: We assess your current eating habits, nutritional needs, and any dietary restrictions, then build a realistic, sustainable plan focused on portion control, balanced nutrition, and nutrient-dense foods not restrictive fad diets
